{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:17:40Z","timestamp":1791908260750,"version":"4.3.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jcf.2025.05.006","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T15:46:56Z","timestamp":1749224816000},"page":"792-800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Fecal microbiota changes in people with cystic fibrosis after 6 months of elexacaftor\/tezacaftor\/ivacaftor: Findings from the promise study"],"prefix":"10.1016","volume":"24","author":[{"given":"Jennifer T","family":"Duong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary S","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian J","family":"Verster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carson","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Kelsi Penewit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Salipante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George M","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Jane","family":"Schwarzenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas R","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10059","key":"10.1016\/j.jcf.2025.05.006_bib0001","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet Lond Engl"},{"issue":"6","key":"10.1016\/j.jcf.2025.05.006_bib0002","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/MCP.0b013e3283659ef2","article-title":"Intestinal complications of cystic fibrosis","volume":"19","author":"Borowitz","year":"2013","journal-title":"Curr Opin Pulm Med"},{"issue":"9","key":"10.1016\/j.jcf.2025.05.006_bib0003","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009753","article-title":"The cystic fibrosis intestine","volume":"3","author":"De Lisle","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"10.1016\/j.jcf.2025.05.006_bib0004","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrgastro.2015.226","article-title":"Cystic fibrosis from the gastroenterologist\u2019s perspective","volume":"13","author":"Ooi","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jcf.2025.05.006_bib0005","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/MPG.0000000000000683","article-title":"Intestinal inflammation and impact on growth in children with cystic fibrosis","volume":"60","author":"Dhaliwal","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"10.1016\/j.jcf.2025.05.006_bib0006","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/MPG.0b013e3181d1b013","article-title":"Evidence of intestinal inflammation in patients with cystic fibrosis","volume":"51","author":"Werlin","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"10.1016\/j.jcf.2025.05.006_bib0007","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11894-017-0546-0","article-title":"The enigmatic gut in Cystic fibrosis: linking inflammation, dysbiosis, and the increased risk of malignancy","volume":"19","author":"Garg","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"issue":"2","key":"10.1016\/j.jcf.2025.05.006_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116967","article-title":"Intestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis","volume":"10","author":"Flass","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jcf.2025.05.006_bib0009","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jcf.2012.10.003","article-title":"Dysbiosis of bifidobacteria and Clostridium cluster XIVa in the cystic fibrosis fecal microbiota","volume":"12","author":"Duytschaever","year":"2013","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"4","key":"10.1016\/j.jcf.2025.05.006_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061176","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) allelic variants relate to shifts in faecal microbiota of cystic fibrosis patients","volume":"8","author":"Schippa","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jcf.2025.05.006_bib0011","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.1038\/s41598-017-06880-y","article-title":"A pilot study demonstrating the altered gut microbiota functionality in stable adults with Cystic Fibrosis","volume":"7","author":"Fouhy","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.jcf.2025.05.006_bib0012","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3390\/jcm11030649","article-title":"Intestinal inflammation and alterations in the gut microbiota in Cystic Fibrosis: a review of the current evidence, pathophysiology and future directions","volume":"11","author":"Tam","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcf.2025.05.006_bib0013","doi-asserted-by":"crossref","DOI":"10.1038\/srep22493","article-title":"Metagenomic evidence for taxonomic dysbiosis and functional imbalance in the gastrointestinal tracts of children with cystic fibrosis","volume":"6","author":"Manor","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.jcf.2025.05.006_bib0014","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/cid\/cit715","article-title":"Escherichia coli dysbiosis correlates with gastrointestinal dysfunction in children with cystic fibrosis","volume":"58","author":"Hoffman","year":"2014","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"2","key":"10.1016\/j.jcf.2025.05.006_bib0015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41591-019-0714-x","article-title":"Fecal dysbiosis in infants with cystic fibrosis is associated with early linear growth failure","volume":"26","author":"Hayden","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jcf.2025.05.006_bib0016","doi-asserted-by":"crossref","DOI":"10.1007\/s10620-022-07812-1","article-title":"Cystic fibrosis-related gut dysbiosis: a systematic review","author":"Caley","year":"2023","journal-title":"Dig Dis Sci."},{"issue":"3","key":"10.1016\/j.jcf.2025.05.006_bib0017","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jcf.2021.11.014","article-title":"Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis","volume":"21","author":"Marsh","year":"2022","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"7","key":"10.1016\/j.jcf.2025.05.006_bib0018","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1073\/pnas.1714373115","article-title":"Adaptation of commensal proliferating Escherichia coli to the intestinal tract of young children with cystic fibrosis","volume":"115","author":"Matamouros","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.jcf.2025.05.006_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008251","article-title":"CFTR dysregulation drives active selection of the gut microbiome","volume":"16","author":"Meeker","year":"2020","journal-title":"PLoS Pathog"},{"issue":"1","key":"10.1016\/j.jcf.2025.05.006_bib0020","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/gutjnl-2012-304119","article-title":"Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation","volume":"63","author":"Martinez-Medina","year":"2014","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jcf.2025.05.006_bib0021","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36364-6","article-title":"Impact of CFTR modulation with ivacaftor on gut microbiota and intestinal inflammation","volume":"8","author":"Ooi","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.jcf.2025.05.006_bib0022","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.05.006_bib0023","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jcf.2023.10.001","article-title":"Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged \u226512 years - the RECOVER study","volume":"23","author":"Mainz","year":"2024","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"5","key":"10.1016\/j.jcf.2025.05.006_bib0024","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis: a Clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcf.2025.05.006_bib0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcf.2021.02.003","article-title":"PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy","volume":"20","author":"Nichols","year":"2021","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"3","key":"10.1016\/j.jcf.2025.05.006_bib0026","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jcf.2024.02.015","article-title":"Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor\/tezacaftor\/ivacaftor","volume":"23","author":"Duong","year":"2024","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"19","key":"10.1016\/j.jcf.2025.05.006_bib0027","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.05.006_bib0028","series-title":"Cystic fibrosis foundation. cystic fibrosis foundation patient registry annual data report","year":"2023"},{"issue":"10","key":"10.1016\/j.jcf.2025.05.006_bib0029","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.jcf.2025.05.006_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208171","article-title":"Gut microbiota signatures in cystic fibrosis: loss of host CFTR function drives the microbiota enterophenotype","volume":"13","author":"Vernocchi","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jcf.2025.05.006_bib0031","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03420-24","article-title":"Persistent delay in maturation of the developing gut microbiota in infants with cystic fibrosis","volume":"16","author":"Verster","year":"2025","journal-title":"mBio"},{"issue":"20","key":"10.1016\/j.jcf.2025.05.006_bib0032","doi-asserted-by":"crossref","DOI":"10.1172\/JCI184171","article-title":"Elexacaftor\/tezacaftor\/ivacaftor\u2019s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment","volume":"134","author":"Morgan","year":"2024","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.jcf.2025.05.006_bib0033","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41564-018-0306-4","article-title":"Gut microbiome structure and metabolic activity in inflammatory bowel disease","volume":"4","author":"Franzosa","year":"2019","journal-title":"Nat Microbiol"},{"issue":"1","key":"10.1016\/j.jcf.2025.05.006_bib0034","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13073-017-0490-5","article-title":"A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients","volume":"9","author":"Hall","year":"2017","journal-title":"Genome Med"},{"issue":"5","key":"10.1016\/j.jcf.2025.05.006_bib0035","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s13238-020-00745-3","article-title":"The microbiome in inflammatory bowel diseases: from pathogenesis to therapy","volume":"12","author":"Liu","year":"2021","journal-title":"Protein Cell"},{"issue":"2","key":"10.1016\/j.jcf.2025.05.006_bib0036","doi-asserted-by":"crossref","first-page":"fuad014","DOI":"10.1093\/femsre\/fuad014","article-title":"Ruminococcus gnavus: friend or foe for human health","volume":"47","author":"Crost","year":"2023","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.jcf.2025.05.006_bib0037","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41698-019-0101-6","article-title":"Characterization of mucosal dysbiosis of early colonic neoplasia","volume":"3","author":"Hong","year":"2019","journal-title":"NPJ Precis Oncol"},{"issue":"7","key":"10.1016\/j.jcf.2025.05.006_bib0038","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1111\/1462-2920.13401","article-title":"Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis","volume":"18","author":"Lv","year":"2016","journal-title":"Environ Microbiol"},{"issue":"7533","key":"10.1016\/j.jcf.2025.05.006_bib0039","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nature13828","article-title":"Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile","volume":"517","author":"Buffie","year":"2015","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jcf.2025.05.006_bib0040","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.cell.2016.05.041","article-title":"From dietary Fiber to host physiology: short-chain fatty acids as key bacterial metabolites","volume":"165","author":"Koh","year":"2016","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jcf.2025.05.006_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19490976.2021.1907272","article-title":"Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease","volume":"13","author":"Stoeva","year":"2021","journal-title":"Gut Microbes"},{"issue":"2","key":"10.1016\/j.jcf.2025.05.006_bib0042","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.jcf.2025.05.006_bib0043","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jcf.2019.03.009","article-title":"An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB)","volume":"18","author":"Rosenfeld","year":"2019","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"5","key":"10.1016\/j.jcf.2025.05.006_bib0044","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jcf.2022.06.002","article-title":"Modulation, microbiota and inflammation in the adult CF gut: a prospective study","volume":"21","author":"Ronan","year":"2022","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"5","key":"10.1016\/j.jcf.2025.05.006_bib0045","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jcf.2020.12.002","article-title":"Changes in fecal microbiota with CFTR modulator therapy: a pilot study","volume":"20","author":"Pope","year":"2021","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"5","key":"10.1016\/j.jcf.2025.05.006_bib0046","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jcf.2024.05.002","article-title":"Impact of extended Elexacaftor\/Tezacaftor\/Ivacaftor therapy on the gut microbiome in cystic fibrosis","volume":"23","author":"Marsh","year":"2024","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"10212","key":"10.1016\/j.jcf.2025.05.006_bib0047","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10.1016\/j.jcf.2025.05.006_bib0048","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cell.2024.10.022","article-title":"Fecal microbial load is a major determinant of gut microbiome variation and a confounder for disease associations","volume":"188","author":"Nishijima","year":"2025","journal-title":"Cell"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325014870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325014870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:14:28Z","timestamp":1778822068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325014870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1569199325014870"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.05.006","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fecal microbiota changes in people with cystic fibrosis after 6 months of elexacaftor\/tezacaftor\/ivacaftor: Findings from the promise study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}